In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Driving Oncology: ImmunoGen CEO Mark Enyedy on Biopharma’s Year Ahead

Executive Summary

Cancer continues to reign in 2018 as the emperor of all maladies, with almost boundless opportunities for companies with a solid base in new science and a differentiated therapy set that can be tailored to the needs of individual patients not served by the current standard of care. ImmunoGen CEO Mark Enyedy tells In Vivo that there’s never been a better time for drugmakers in the oncology marketplace.

Advertisement

Related Content

Biopharma 2018: Is There Still A Place For Pharma In The New Health Care Economy?
ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV005275

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel